STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Bright Minds Biosciences (NASDAQ: DRUG) will present at two industry events in early December 2025 highlighting its work on selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other CNS disorders.

Events and schedule: Piper Sandler 37th Annual Healthcare Conference on Dec 3, 2025 at 11:30am ET, and the 2025 American Epilepsy Society Annual Meeting scientific exhibit session on Dec 7, 2025 from 2:00pm–5:00pm ET. The appearances provide investor and scientific audiences opportunities to hear updates and view the company’s scientific exhibit.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will participate in the following upcoming events:

 EVENT:Piper Sandler 37th Annual Healthcare Conference
 DATE: Wednesday, December 3, 2025
 TIME:11:30am ET
   
 EVENT:2025 American Epilepsy Society Annual Meeting – Scientific Exhibit Session
 DATE:Sunday, December 7, 2025
 TIME:2pm – 5pm ET
   

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com


FAQ

When will Bright Minds Biosciences (DRUG) present at the Piper Sandler Healthcare Conference?

Bright Minds will present on Dec 3, 2025 at 11:30am ET.

What is the date and time for Bright Minds' exhibit at the 2025 American Epilepsy Society meeting?

The scientific exhibit session is scheduled for Dec 7, 2025 from 2:00pm–5:00pm ET.

What topics will Bright Minds Biosciences (DRUG) cover at the December 2025 events?

The company will highlight its development of selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other CNS disorders.

How can investors find Bright Minds' presentation details for the Dec 3, 2025 Piper Sandler event?

Investors should check the Piper Sandler conference schedule and Bright Minds investor relations for presentation access and timing details.

Will Bright Minds (DRUG) provide scientific materials at the American Epilepsy Society exhibit on Dec 7, 2025?

The company will participate in a scientific exhibit session, where attendees can view the company’s exhibit and related materials during the 2:00pm–5:00pm ET slot.

Do these December 2025 events signal a regulatory or financial update from Bright Minds (DRUG)?

The announcements list presentation and exhibit dates and times; they do not include specific regulatory decisions or financial guidance.
Bright Minds Biosciences Inc

NASDAQ:DRUG

DRUG Rankings

DRUG Latest News

DRUG Latest SEC Filings

DRUG Stock Data

428.65M
5.04M
22.42%
73.98%
2.79%
Biotechnology
Healthcare
Link
United States
New York